百利天恒于11月7日至11月12日招股 预计11月17日上市

Group 1 - The company, Baili Tianheng, plans to conduct an initial public offering (IPO) from November 7 to November 12, 2025, with a global offering of 8.6343 million shares, where 10% is allocated for Hong Kong and 90% for international sales, with an additional 15% over-allotment option [1] - The expected share price range is between 347.5 and 389 HKD per share, with trading anticipated to commence on November 17, 2025 [1] - The company operates as a comprehensive medical enterprise group with capabilities in early-stage research, clinical development, production, and commercialization, focusing on innovative biopharmaceuticals and generic medicines, including traditional Chinese medicine [1] Group 2 - Ten years ago, the company established SystImmune in Seattle, USA, and began developing iza-bren (BL-B01D1), the world's first and only EGFR×HER3 bispecific antibody ADC to enter Phase III clinical development [2] - Recently, the company entered into a global strategic licensing and collaboration agreement with BMS for iza-bren, valued at 8.4 billion USD, with an upfront payment of 800 million USD, marking the largest single asset transaction in the ADC field to date [2] - Over the past decade, the company has built an innovative ADC drug development platform, successfully developing 10 ADC candidates that have entered clinical stages, conducting approximately 70 clinical studies, including 16 key registration trials in China and 3 global key registration trials [2]